Treatment Outcomes with Lanadelumab Every 2 Weeks and Garadacimab are Very Similar in Patients with Hereditary Angioedema
Drugs in R&D · 2026-03 · 26 (1) · 31-33
DOI: 10.1007/s40268-026-00539-8 ↗Kurz gefasst
Leserbrief in der Zeitschrift Drugs in R&D, online erschienen am 28.03.2026. Verfasst von Irmgard Andresen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland. irmgard.andresen@takeda.com. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Development Center Americas, Inc.
Abstract (Originalsprache)
We read with interest the recent publication
Autor:innen und Institutionen
- Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland. irmgard.andresen@takeda.com.
- Takeda Development Center Americas, Inc., Lexington, MA, USA.
- Takeda Pharmaceuticals USA, Inc., Cambridge, MA, USA.
Förderung
- Takeda Development Center Americas, Inc
Zitieren
APA
Andresen, I., Khutoryansky, N., Feeny, S. L., & Dangel, A. (2026). Treatment Outcomes with Lanadelumab Every 2 Weeks and Garadacimab are Very Similar in Patients with Hereditary Angioedema. Drugs in R&D, 26(1), 31-33. https://doi.org/10.1007/s40268-026-00539-8
Vancouver
Andresen I, Khutoryansky N, Feeny SL, Dangel A. Treatment Outcomes with Lanadelumab Every 2 Weeks and Garadacimab are Very Similar in Patients with Hereditary Angioedema. Drugs in R&D. 2026;26(1):31-33. doi:10.1007/s40268-026-00539-8
BibTeX
@article{Andresen2026,
author = {Andresen, Irmgard and Khutoryansky, Natalie and Feeny, Sarah L and Dangel, Alissa},
title = {Treatment Outcomes with Lanadelumab Every 2 Weeks and Garadacimab are Very Similar in Patients with Hereditary Angioedema},
journal = {Drugs in R&D},
year = {2026},
volume = {26},
number = {1},
pages = {31--33},
doi = {10.1007/s40268-026-00539-8}
}
EUVIMED